This Phase IIb trial is an important milestone for Oramed as it will test its first indication for ORMD-0801 on a large group of volunteers for the duration of six weeks. This six week randomized, double blind placebo controlled study will be performed in three locations in Cape Town, South Africa.
OnQ Consulting, a clinical research organization located in Johannesburg, South Africa, will oversee the clinical trials.
Nadav Kidron, CEO of Oramed, said: “We are pleased to begin this study of ORMD-0801 on type 2 diabetes patients following our successful Phase IIa clinical trials in August 2008.”